Section 3
Chapter 2,694

Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB) : structure-activity studies of the lipophilic and geometric parameters of polyarylated acyl analogs of ECB

Debono, M.; Turner, W.W.; LaGrandeur, L.; Burkhardt, F.J.; Nissen, J.S.; Nichols, K.K.; Rodriguez, M.J.; Zweifel, M.J.; Zeckner, D.J.; Gordee, R.S.

Journal of Medicinal Chemistry 38(17): 3271-3281


ISSN/ISBN: 0022-2623
PMID: 7650681
DOI: 10.1021/jm00017a012
Accession: 002693468

Echinocandin B (ECB) is a lipopeptide composed of a complex cyclic peptide acylated at the N-terminus by linoleic acid. Enzymatic deacylation of ECB provided the peptide "nucleus" as a biologically inactive substrate from which novel ECB analogs were generated by chemical reacylation at the N-terminus. Varying the acyl group revealed that the structure and physical properties of the side chain, particularly its geometry and lipophilicity, played a pivotal role in determining the antifungal potency properties of the analog. Using CLOGP values to describe and compare the lipophilicities of the side chain fragments, it was shown that values of > 3.5 were required for expression of antifungal activity. Secondly, a linearly rigid geometry of the side chain was the most effective shape in enhancing the antifungal potency. Using these parameters as a guide, a variety of novel ECB analogs were synthesized which included arylacyl groups that incorporated biphenyl, terphenyl, tetraphenyl, and arylethynyl groups. Generally the glucan synthase inhibition by these analogs correlated well with in vitro and in vivo activities and was likewise influenced by the structure of the side chain. These structural variations resulted in enhancement of antifungal activity in both in vitro and in vivo assays. Some of these analogs, including LY303366 (14a), were effective by the oral route of administration.

PDF emailed within 0-6 h: $19.90